Antiviral treatment for chronic hepatitis B infection in renal transplant recipients

[1]  G. Süleymanlar,et al.  Effect of prophylactic versus preemptive lamivudine treatment and tenofovir on HBsAg+ kidney transplant recipients. , 2015, Experimental and Clinical Transplantation.

[2]  M. Yuen,et al.  Entecavir treatment in kidney transplant recipients infected with hepatitis B , 2014, Clinical transplantation.

[3]  G. Yin,et al.  Efficacy and safety of tenofovir in a kidney transplant patient with chronic hepatitis B and nucleos(t)ide multidrug resistance: a case report , 2014, Journal of Medical Case Reports.

[4]  K. Chow,et al.  Hepatocellular carcinoma after kidney transplantation: analysis of Hong Kong Renal Registry , 2014, Renal failure.

[5]  J.H. Cho,et al.  Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection , 2014, Transplant infectious disease : an official journal of the Transplantation Society.

[6]  B. McMahon.  Chronic hepatitis B virus infection. , 2014, The Medical clinics of North America.

[7]  M. Buti,et al.  Telbivudine improves renal function in patients with chronic hepatitis B. , 2014, Gastroenterology.

[8]  Ning Wang,et al.  Prevalence and risk factors of hepatitis C and B virus infections in hemodialysis patients and their spouses: A multicenter study in Beijing, China , 2013, Journal of medical virology.

[9]  J. Park,et al.  Long-term outcome of Hepatitis B-positive renal allograft recipients after development of antiviral treatment. , 2012, Clinical nephrology.

[10]  Chun-Che Lin,et al.  Safety and efficacy of adefovir therapy for lamivudine-resistant hepatitis B virus infection in renal transplant recipients. , 2012, Journal of the Formosan Medical Association = Taiwan yi zhi.

[11]  R. Gish,et al.  Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  T. Hu,et al.  A Novel Experience of Antiviral Therapy for Chronic Hepatitis B in Renal Transplant Recipients , 2012, Antiviral therapy.

[13]  M. Yuen,et al.  Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance, and Clinical Safety , 2011, The American Journal of Gastroenterology.

[14]  P. Messa,et al.  Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  Y. Liaw,et al.  Efficacy and safety of prolonged 3‐year telbivudine treatment in patients with chronic hepatitis B , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[16]  L. Rostaing,et al.  Tenofovir Therapy in Hepatitis B Virus-Positive Solid-Organ Transplant Recipients , 2011, Transplantation.

[17]  M. Yuen,et al.  Long-Term Outcome of Renal Transplant Recipients With Chronic Hepatitis B Infection—Impact of Antiviral Treatments , 2010, Transplantation.

[18]  T. Chan,et al.  Response to adefovir or entecavir in renal allograft recipients with hepatitic flare due to lamivudine‐resistant hepatitis B , 2010, Clinical transplantation.

[19]  C. Thio,et al.  Tenofovir for the Treatment of Hepatitis B Virus , 2009, Pharmacotherapy.

[20]  Ronald E. Rose,et al.  Long‐term monitoring shows hepatitis B virus resistance to entecavir in nucleoside‐naïve patients is rare through 5 years of therapy , 2009, Hepatology.

[21]  L. Rostaing,et al.  Renal side effects of adefovir in hepatitis B virus-(HBV) positive kidney allograft recipients. , 2009, Clinical nephrology.

[22]  L. Rostaing,et al.  Entecavir Therapy for Adefovir-Resistant Hepatitis B Virus Infection in Kidney and Liver Allograft Recipients , 2008, Transplantation.

[23]  H. Tillmann,et al.  Telbivudine versus lamivudine in patients with chronic hepatitis B. , 2008, The New England journal of medicine.

[24]  George Kitis,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. , 2006, Gastroenterology.

[25]  H. J. de Silva,et al.  Treatment of lamivudine-resistant hepatitis B infection in post-renal transplant patients with adefovir dipivoxil: preliminary results. , 2006, Transplantation proceedings.

[26]  H. Karakayalı,et al.  Lamivudine therapy in kidney allograft recipients who are seropositive for hepatitis B surface antigen. , 2006, Transplantation proceedings.

[27]  F. Fabrizi,et al.  HBsAg Seropositive Status and Survival After Renal Transplantation: Meta‐Analysis of Observational Studies , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[28]  S. Pol,et al.  Efficacy and Safety of Adefovir Dipivoxil in Kidney Recipients, Hemodialysis Patients, and Patients with Renal Insufficiency , 2005, Transplantation.

[29]  Hassane Izzedine,et al.  Antiviral drug-induced nephrotoxicity. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  A. Mazuecos,et al.  Treatment with adefovir dipivoxil in a renal transplant patient with renal insufficiency and lamivudine-resistant hepatitis B infection. , 2005, Transplantation proceedings.

[31]  T. Hannedouche,et al.  Tenofovir-induced acute renal failure in an HIV patient with normal renal function. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[32]  D. Thabut,et al.  Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B , 2004, European journal of gastroenterology & hepatology.

[33]  T. Chan,et al.  Prospective Study on Lamivudine‐Resistant Hepatitis B in Renal Allograft Recipients , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[34]  M. Colombo,et al.  Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. , 2004, Gastroenterology.

[35]  F. Fabrizi,et al.  Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials , 2004, Transplantation.

[36]  T. Chan,et al.  Preemptive lamivudine therapy based on HBV DNA level in HBsAg‐positive kidney allograft recipients , 2002, Hepatology.

[37]  B. McMahon,et al.  Chronic hepatitis B , 2001, Hepatology.

[38]  S. Fan,et al.  Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma , 2000, Cancer.

[39]  P Coriat,et al.  Impact of hepatitis B and C virus on kidney transplantation outcome , 1999, Hepatology.

[40]  T. Chan,et al.  Treatment of fibrosing cholestatic hepatitis with lamivudine. , 1998, Gastroenterology.

[41]  Z. Gaciong,et al.  Long-term results of treatment of chronic hepatitis B, C and D with interferon-α in renal allograft recipients , 1998 .

[42]  Z. Gaciong,et al.  Long-term results of treatment of chronic hepatitis B, C and D with interferon-alpha in renal allograft recipients. , 1998, Transplant international : official journal of the European Society for Organ Transplantation.

[43]  L. Rostaing,et al.  Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation. , 1997, Transplantation.

[44]  G. Marchesini,et al.  Efficacy of a surveillance program for early detection of hepatocellular carcinoma , 1996, Cancer.

[45]  F. Carnot,et al.  The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. , 1996, Transplantation.

[46]  L. Rostaing,et al.  Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. , 1996, Nephron.

[47]  C. Yang,et al.  Prevalence and clinical course of hepatitis B and hepatitis C liver disease in ciclosporin-treated renal allograft recipients. , 1995, Nephron.

[48]  Y. Kanno,et al.  Hepatitis virus infection (HBV and HCV) in eleven Japanese hemodialysis units. , 1992, Clinical nephrology.

[49]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[50]  T. Hutchinson,et al.  THE IMPACT OF RENAL TRANSPLANTATION ON THE COURSE OF HEPATITIS B LIVER DISEASE , 1985, Transplantation.

[51]  Y. Pirson,et al.  Long-term effect of hbs antigenemia on patient survival after renal transplantation. , 1977, The New England journal of medicine.